Global Information
회사소개 | 문의 | 비교리스트

전체 게놈 및 엑솜 시퀀싱(WGES) 시장 : 연구, 임상, 종양, 병원균, Agribio, 소비자별 - 이그제큐티브 가이드 및 컨설턴트 가이드(Sars-cov-2의 전체 게놈 시퀀스 포함) 2020-2024년

Whole Genome and Exome Sequencing Markets by Research, Clinical, Tumor, Pathogen, Agribio & Consumer with Executive and Consultant Guides. (Including the Whole Genome Sequence of Sars-cov-2) 2020 to 2024

리서치사 Howe Sound Research
발행일 2020년 06월 상품 코드 943429
페이지 정보 영문 528 Pages
가격
US $ 6,995 ₩ 8,266,000 PDF by E-mail (Single User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 1대의 PC에서만 이용할 수 있는 라이선스로 인쇄가 불가능합니다.
US $ 10,495 ₩ 12,402,000 PDF by E-mail (Five User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 5대의 PC에서만 이용할 수 있는 라이선스로 인쇄가 불가능합니다.
US $ 13,995 ₩ 16,539,000 PDF by E-mail (Enterprise License) help
동일기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 편집 및 인쇄는 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



전체 게놈 및 엑솜 시퀀싱(WGES) 시장 : 연구, 임상, 종양, 병원균, Agribio, 소비자별 - 이그제큐티브 가이드 및 컨설턴트 가이드(Sars-cov-2의 전체 게놈 시퀀스 포함) 2020-2024년 Whole Genome and Exome Sequencing Markets by Research, Clinical, Tumor, Pathogen, Agribio & Consumer with Executive and Consultant Guides. (Including the Whole Genome Sequence of Sars-cov-2) 2020 to 2024
발행일 : 2020년 06월 페이지 정보 : 영문 528 Pages

세계의 전체 게놈 및 엑솜 시퀀싱(WGES: Whole Genome and Exome Sequencing) 시장에 대해 조사했으며, 시장 규모, 성장 촉진요인 및 억제요인, 최근의 개발 진전, 용도·유기체·지역별 시장 분석, 경쟁 상황, 주요 기업 프로파일 등의 정보를 제공합니다.

목차

i : 전략적 상황 분석 및 코로나19(COVID-19)의 영향

ii 경영진, 마케팅, 영업, 사업 개발 직원을 위한 가이드

iii : 경영 컨설팅 및 자문을 위한 가이드

제1장 서론 및 시장 정의

  • 정의
    • 전체 게놈 및 엑솜 시퀀싱(WGES)
    • 조사와 임상
    • 임상 종양
    • 임상 병원체
    • 농업/기타
    • D2C(Direct to Consumer)
  • 유전체학 혁명
  • 시장의 정의
    • 매출 기준 시장 규모
  • 미국의 의료 시장과 임상 검사 : 전망
    • 임상시험을 위한 미국의 메디케어 지출
  • 게놈 규모
    • 비용, 가격과 게놈 규모, 가격 설정

제2장 시장 개요

  • 시장 진출기업
    • 기기 제조업체
    • 독립 연구소 : 특수/벽지
    • 독립 연구소 : 국가/지역
    • 독립 연구소 : 분석
    • 공국립/지역 연구소
    • 병원 실험실
    • 의사 실험실
    • DTC Lab
    • 시퀀싱 실험실
    • 감사기관
  • 시장, 사례, 고찰
    • DTC(Direct to Consumer) : 두 가지 접근 방법
    • 연구 시장
    • Clinical-Understanding Germline and Somatic
    • 병원체 검사
    • AgriBio : 큰 사업
  • 산업 구조
    • 병원의 검사 점유율
    • 규모의 경제
    • 기기 제조업체의 역할
    • 의료 업계의 영향

제3장 시장 동향

  • 성장 촉진요인
    • 진단 요인
    • 기타 코드 해석
    • 농업의 변화
    • 불임 치료 기술의 도래
    • 병원체의 과제
  • 성장 억제요인
    • 기업간 경쟁 심화에 의한 저가화
    • 저가화
    • 의료 비용의 우려
    • 웰니스의 단점
    • GMO 반대 운동
  • 시퀀싱 계측
    • 비용 감소에 의한 산업 구조 변화
    • 현재의 NGS 기기 사양 리스트
    • Illumina
    • ION
    • Pacific Biosystems
    • Roche
    • SOLiD
    • Oxford Nanopore
    • Targeted Sequencing에 대한 CRISPR 채용
    • 새로운 시퀀싱 기술 등

제4장 WGES의 최근 발전

  • 최근 발전

제5장 주요 기업 개요

  • 10x Genomics, Inc.
  • 23andME Inc.
  • Abbott Diagnostics
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Agena Bioscience, Inc.
  • Agilent
  • Akonni Biosystems
  • Ancestry.com LLC
  • Anchor Dx
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioM & eacute; rieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne
  • C2i Genomics
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Centogene
  • Chronix Biomedical
  • Circulogene
  • Clear Labs
  • Clinical Genomics
  • Complete Genomics, Inc.-A BGI Company
  • Cynvenio
  • Dante Labs
  • Datar Cancer Genetics Limited
  • Day Zero Diagnostics
  • Diasorin SpA
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Excellerate Bioscience
  • Exosome Diagnostics
  • Fabric Genomics
  • Fluidigm Corp
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • Fulgent Genetics
  • GE Global Research
  • GE Healthcare Life Sciences
  • Gencove
  • Genedrive
  • GeneFirst Ltd.
  • Genetron Health(Beijing) Co., Ltd.
  • Genewiz
  • Genomic Health
  • Genomics England
  • Genomics Personalized Health(GPH)
  • GenomOncology
  • Genzyme Corporation
  • Grail, Inc.
  • Grifols
  • Guardant Health
  • Guardiome
  • HeiScreen
  • Helix
  • Helomics
  • Hologic
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Invitae Corporation
  • Invivoscribe
  • Karius
  • Macrogen
  • MDNA Life SCIENCES, Inc.
  • MDx Health
  • Medgenome
  • Meridian Bioscience
  • Mesa Biotech
  • MIODx
  • miR Scientific
  • MNG Labs
  • Molecular MD
  • NantHealth, Inc.
  • Natera
  • Nebula Genomics
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Omega Bioservices
  • OncoDNA
  • OpGen
  • ORIG3N, Inc.
  • Origene Technologies
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Protagen Diagnostics
  • Qiagen Gmbh
  • Quantumdx
  • Regeneron
  • Roche Molecular Diagnostics
  • Roswell Biotechnologies
  • Seegene
  • Sequencing.com
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • SkylineDx
  • Stratos Genomics
  • Sure Genomics, Inc.
  • Sysmex
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Veritas Genetics
  • Volition

제6장 세계 시장

  • 국가별
  • 용도별
  • 유기체

제7장 시장 분석 : 용도별

  • 조사
  • 임상 인체
  • 임상 종양
  • 임상 병원체
  • D2C
  • 농업/기타

제8장 시장 분석 : 유기체별

  • 인간
  • 병원균
  • 기타 생물

제9장 전체 게놈 시퀀싱의 미래

부록

  • i. 미국의 메디케어 시스템 : 2020년 1월의 실험실 요금 스케줄
  • II SARS-CoV-2의 전체 게놈 시퀀스
  • III 조사 방법
LSH 20.07.07

Table of Tables

  • Table 1: The Base Pairs
  • Table 2: Most Common Traditional Genetic Disorders
  • Table 3: Lab Spending 2014 to 2024
  • Table 4: List of GLOBAL SEQUENCING LOCATIONS
  • Table 5: Market Players by Type
  • Table 6: The Different Markets for Whole Genome Sequencing
  • Table 7: DTC Sub Segments
  • Table 8: Roles of WGS in AgriBio
  • Table 9: The Factors Driving Growth
  • Table 10: Factors Limiting Growth
  • Table 11: - Listing of Current NGS Instrument Specifications
  • Table 12: Six New Sequencing Technologies
  • Table 13: - Global Companion Diagnostic Market by Region
  • Table 14: Global Market by Application
  • Table 15: Global Market by Organism
  • Table 16: Research by Country
  • Table 17: Clinical Human by Country
  • Table 18: Clinical Tumor by Country
  • Table 19: Clinical Pathogen by Country
  • Table 20: Direct to Consumer by Country
  • Table 21: Agriculture/Other by Country
  • Table 22: Human by Country
  • Table 23: Pathogen by Country
  • Table 24: Other Organism by Country
  • Table 25: 2020 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1: Clinical Lab Spending 2014 to 2024
  • Figure 2: Size of Genome for Various Species
  • Figure 3: - Cost To Sequence a Human Genome
  • Figure 4: Base Year Country Market Share Chart
  • Figure 5: CDx Market by Application - Base vs. Final Year
  • Figure 6: CDx Market by Application Base Year
  • Figure 7: CDx Market by Application Final Year
  • Figure 8: Application Type Share by Year
  • Figure 9: by Application Segment Growth
  • Figure 10: by Organism - Base vs. Final Year
  • Figure 11: by Organism Market Base Year
  • Figure 12: by Organism Market Final Year
  • Figure 13: by Organism Share by Year
  • Figure 14: by Organism Segment Growth
  • Figure 15: Research Growth
  • Figure 16: Clinical Human Growth
  • Figure 17: Clinical Tumor Growth
  • Figure 18: Clinical Pathogen Growth
  • Figure 19: Direct to Consumer Growth
  • Figure 20: Agriculture/Other Growth
  • Figure 21: Human Growth
  • Figure 22: Pathogen Growth
  • Figure 23: Other Organism Growth

OVERVIEW:

The COVID Pandemic has created a surge in Whole Genome Sequencing of Pathogens but cancer related activity has suffered. Find out all about it in the comprehensive report of Whole Genome Sequencing. The complete genome of the COVID virus is included as an example of the work being done.

Will all newborns receive Whole Genome Sequencing at birth? How fast will Direct to Consumer Testing grow? What sequencing technology will take the lead? What's holding the industry back? Where are the over 800 locations that have high throughput devices?

Our facts and support = Your success.

A plummeting of costs for Whole Genome Sequencing is creating a gold rush for market players. New consumers, new technologies, new specializations. In a situation reminiscent of the birth of the internet industry a wide range of well funded players are racing for market share on a truly global stage. The report forecasts the market size out to 2023. The report includes detailed breakouts for 14 countries and 5 regions.

Tumor Cell Sequencing? Direct to Consumer? Gene Expression? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities, and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

All report data is available in Excel format on request. Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Whole Genome Sequencing Market - Strategic Situation Analysis & COVID Impact

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1. Whole Genome Sequencing Definition In This Report
    • 1.1.1. Whole and Exome Sequencing
    • 1.1.2. Research and Clinical
    • 1.1.3. Clinical Tumor
    • 1.1.4. Clinical Pathogen
    • 1.1.5. Agri/Other
    • 1.1.6. Direct to Consumer
  • 1.2. The Genomics Revolution
  • 1.3. Market Definition
    • 1.3.1. Revenue Market Size
  • 1.4. U.S. Medical Market and laboratory Testing - Perspective
    • 1.4.1. U.S. Medicare Expenditures for laboratory testing
  • 1.5. Sizing the Genome-Not What You Think
    • 1.5.1. Cost, Price and Genome Size, Pricing Practice

1A GLOBAL LISTING OF HIGH THROUGHPUT SEQUENCING ESTABLISHMENTS INSTALLED BASE-Location & Contacts

2. Market Overview

  • 2.1. Market Participants Play Different Roles
    • 2.1.1. Instrument Manufacturer
    • 2.1.2. Independent lab specialized/esoteric
    • 2.1.3. Independent lab national/regional
    • 2.1.4. Independent lab analytical
    • 2.1.5. Public National/regional lab
    • 2.1.6. Hospital lab
    • 2.1.7. Physician lab
    • 2.1.8. DTC Lab
    • 2.1.9. Sequencing Labs
    • 2.1.10. Audit body
  • 2.2. Whole Genome Sequencing -Markets, Examples and Discussion
    • 2.2.1. Direct to Consumer-Two Approaches
      • 2.2.1.1. The New Age of Medical Information
      • 2.2.1.2. Dangers in DTC-WGS-Health Costs and Regulation
      • 2.2.1.3. Newborn and Prenatal-A Brave New World
      • 2.2.1.4. DTC-How Many Segments?
    • 2.2.2. Research Markets
      • 2.2.2.1. Research Funding and Capital Expense
      • 2.2.2.2. WGS Datasets Preferred
      • 2.2.2.3. Existing research repurposed
      • 2.2.2.4. Organism Wide Market
      • 2.2.2.5. Service Suppliers Respond
    • 2.2.3. Clinical-Understanding Germline and Somatic
      • 2.2.3.1. Somatic-Chasing Mutations and Pharmacogenomics
    • 2.2.4. Pathogen Testing
      • 2.2.4.1. The Hepatitis C Story
      • 2.2.4.2. Will the Microbiology Department Disappear?
    • 2.2.5. AgriBio-Big Business
      • 2.2.5.1. GMO is Here to Stay
      • 2.2.5.2. WGS Benefits and Risks
      • 2.2.5.3. The New Agriculture
  • 2.3. Industry Structure
    • 2.3.1. Hospital's Testing Share
    • 2.3.2. Economies of Scale
    • 2.3.3. Instrument Manufacturer Role
    • 2.3.4. Healthcare Industry Impacts-Still Struggling
      • 2.3.4.1. Can the Healthcare Industry Adapt?
      • 2.3.4.2. Genetic Counselling as an Industry
      • 2.3.4.3. WGES Adoption and Cannibalization
      • 2.3.4.4. The Meaning of Grail

3. Market Trends

  • 3.1. Factors Driving Growth
    • 3.1.1. Diagnostic Factors
    • 3.1.2. Interpreting the Code Otherwise
    • 3.1.3. Changes in Agriculture
    • 3.1.4. Fertility Technology Comes of Age
    • 3.1.5. Pathogen Challenges
  • 3.2. Factors Limiting Growth
    • 3.2.1. Increased Competition Lowers Price
    • 3.2.2. Lower Costs
    • 3.2.3. Healthcare Cost Concerns Curtail Growth
    • 3.2.4. Wellness has a downside
    • 3.2.5. GMO Opposition Movement
  • 3.3. Sequencing Instrumentation
    • 3.3.1. Instrumentation Tenacity
    • 3.3.2. Declining Cost Changes Industry Structure
    • 3.3.3. LISTING of CURRENT NGS INSTRUMENT SPECIFICATIONS
    • 3.3.4. Illumina
    • 3.3.5. ION
    • 3.3.6. Pacific Biosystems
    • 3.3.7. Roche 454
    • 3.3.8. SOLiD
    • 3.3.9. Oxford Nanopore
      • 3.3.9.1. What is Oxford Nanopore Sequencing?
      • 3.3.9.2. What can Oxford Nanopore Sequencingt be used for?
      • 3.3.9.3. Oxford Nanopore Products
    • 3.3.10. Long Reads-Further Segmentation
    • 3.3.11. Linked Reads
    • 3.3.12. Targeted Sequencing Adopts CRISPR
    • 3.3.13. New Sequencing Technologies
      • 3.3.13.1. RNAP sequencing
      • 3.3.13.2. In vitro virus high-throughput sequencing
      • 3.3.13.3. Tunnelling currents DNA sequencing
      • 3.3.13.4. Sequencing by hybridization
      • 3.3.13.5. Sequencing with mass spectrometry
      • 3.3.13.6. Microfluidic Sanger sequencing
      • 3.3.13.7. Microscopy-based techniques

4. WGES Recent Developments

  • 4.1. Recent Developments-Importance and How to Use This Section
    • 4.1.1. Importance of These Developments
    • 4.1.2. How to Use This Section
      • Illumina Achieves First FDA EAU for NGS-Based SARS-CoV-2 Test
      • C2i Genomics to Launch Trials for MRD Detection Tech
      • Roche Acquires Sequencing Company Stratos Genomics
      • UK COVID-19 Sequencing Consortium Launches With £20M in Government, Wellcome Trust Funding
      • Invitae Acquires Three Companies: YouScript, Genelex, Diploid
      • Experience From Centralized Genomic Medicine Lab
      • MGI to Enable $100 Human Genome
      • Nebula Genomics offers $299 WGS
      • Team to Study Campylobacter Omics
      • Veritas Genetics Restarts US Business
      • NEOGEN, Gencove partner to advance animal genomics
      • UK Whole-Genome Sequencing Project Obtains £200M
      • WGS may help with disease outbreaks
      • Veritas Cuts WGS Price by 40%
      • Dante Labs Launches GenomeL, Long Reads Human Whole Genome Sequencing
      • Machine-learning system used to diagnose genetic diseases
      • Whole Genome Sequencing for healthy creates controversy
      • 100,000 whole genomes sequenced in the NHS
      • Nebula Genomics Offers FREE Whole Genome Sequencing
      • Veritas Genetics has time limited WGS offer for $199
      • Veritas Genetics Launches Two New Whole Genome Sequencing Products
      • BGI unveils a powerful new sequencer
      • State of California Funds $2M Whole-Genome Sequencing Pilot

5. Profiles of Key Companies

  • 10x Genomics, Inc.
  • 23andME Inc.
  • Abbott Diagnostics
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Agena Bioscience, Inc.
  • Agilent
  • Akonni Biosystems
  • Ancestry.com LLC
  • Anchor Dx
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne
  • C2i Genomics
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Centogene
  • Chronix Biomedical
  • Circulogene
  • Clear Labs
  • Clinical Genomics
  • Complete Genomics, Inc.-A BGI Company
  • Cynvenio
  • Dante Labs
  • Datar Cancer Genetics Limited
  • Day Zero Diagnostics
  • Diasorin S.p.A.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Excellerate Bioscience
  • Exosome Diagnostics
  • Fabric Genomics
  • Fluidigm Corp
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • Fulgent Genetics
  • GE Global Research
  • GE Healthcare Life Sciences
  • Gencove
  • Genedrive
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co., Ltd.
  • Genewiz
  • Genomic Health
  • Genomics England
  • Genomics Personalized Health (GPH)
  • GenomOncology
  • Genzyme Corporation
  • Grail, Inc.
  • Grifols
  • Guardant Health
  • Guardiome
  • HeiScreen
  • Helix
  • Helomics
  • Hologic
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Invitae Corporation
  • Invivoscribe
  • Karius
  • Macrogen
  • MDNA Life SCIENCES, Inc.
  • MDx Health
  • Medgenome
  • Meridian Bioscience
  • Mesa Biotech
  • MIODx
  • miR Scientific
  • MNG Labs
  • Molecular MD
  • NantHealth, Inc.
  • Natera
  • Nebula Genomics
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Omega Bioservices
  • OncoDNA
  • OpGen
  • ORIG3N, Inc.
  • Origene Technologies
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Protagen Diagnostics
  • Qiagen Gmbh
  • Quantumdx
  • Regeneron
  • Roche Molecular Diagnostics
  • Roswell Biotechnologies
  • Seegene
  • Sequencing.com
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • SkylineDx
  • Stratos Genomics
  • Sure Genomics, Inc.
  • Sysmex
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Veritas Genetics
  • Volition

6. The Global Market for Whole Genome Sequencing

  • 6.1. Global Market Overview by Country
    • 6.1.1. Table-Global Market by Country
    • 6.1.2. Chart - Global Market by Country
  • 6.2. Global Market by Application - Overview
    • 6.2.1. Table-Global Market by Application
    • 6.2.2. Chart-Global Market by Application-Base/Final Year Comparison
    • 6.2.3. Chart-Global Market by Application-Base Year
    • 6.2.4. Chart-Global Market by Application-Final Year
    • 6.2.5. Chart-Global Market by Application-Share by Year
    • 6.2.6. Chart-Global Market by Application-Segment Growth
  • 6.3. Global Market Organism - Overview
    • 6.3.1. Table-Global Market by Organism
    • 6.3.2. Chart-Global Market by Organism-Base/Final Year Comparison
    • 6.3.3. Chart-Global Market by Organism-Base Year
    • 6.3.4. Chart-Global Market by Organism-Final Year
    • 6.3.5. Chart-Global Market by Organism-Share by Year
    • 6.3.6. Chart-Global Market by Organism-Segment Growth

7. Global Whole Genome Sequencing Markets-By Application

  • 7.1. Research
    • 7.1.1. Table Research-by Country
    • 7.1.2. Chart - Research Growth
  • 7.2. Clinical Human
    • 7.2.1. Table Clinical Human-by Country
    • 7.2.2. Chart - Clinical Human Growth
  • 7.3. Clinical Tumor
    • 7.3.1. Table Clinical Tumor-by Country
    • 7.3.2. Chart - Clinical Tumor Growth
  • 7.4. Clinical Pathogen
    • 7.4.1. Table Clinical Pathogen-by Country
    • 7.4.2. Chart - Clinical Pathogen Growth
  • 7.5. Direct to Consumer
    • 7.5.1. Table Direct to Consumer-by Country
    • 7.5.2. Chart-Direct to Consumer Growth
  • 7.6. Agriculture/Other
    • 7.6.1. Table Agriculture/Other-by Country
    • 7.6.2. Chart-Agriculture/Other Growth

8. Global Whole Genome Sequencing Markets-by Organism

  • 8.1. Human
    • 8.1.1. Table Human-by Country
    • 8.1.2. Chart - Human Growth
  • 8.2. Pathogen
    • 8.2.1. Table Pathogen-by Country
    • 8.2.2. Chart - Pathogen Growth
  • 8.3. Other Organism
    • 8.3.1. Table Other Organism-by Country
    • 8.3.2. Chart - Other Organism Growth

9. Vision of the Future of Whole Genome Sequencing

Appendices

  • I. United States Medicare System: January 2020 laboratory Fees Schedule
  • II The Whole Genome Sequence of SARS-CoV-2
  • III Methodology
  • II.1. Authors
  • II.2. Sources
Back to Top
전화 문의
F A Q